IGC Pharma, Inc. is drawing attention in the biotech sector as it progresses with its AI-driven Alzheimer’s therapies, particularly through the ongoing Phase 2 CALMA clinical trial for its candidate IGC-AD1. The trial has reached about 80% patient enrollment, nearing its goal of 146 participants.
The company is expanding its clinical trial network with new sites in New York and leveraging a national clinical network to enhance enrollment efforts. IGC Pharma is committed to integrating AI technologies into its strategy for Alzheimer’s drug discovery and precision medicine. Recently, it filed new patents related to its AI-based data platform, AHA, aimed at improving clinical trial efficiency and patient targeting.
IGC Pharma has also fortified its intellectual property for IGC-AD1, receiving a Notice of Allowance from the Canadian Intellectual Property Office. Financially, the company has ramped up its research and development budget to approximately $1.3 million, while maintaining access to a $12 million credit facility to support its clinical programs and AI initiatives.
In addition to IGC-AD1, the company’s pipeline includes TGR-63, which targets amyloid plaques, and other programs addressing tau proteins and neuroinflammation, showcasing its comprehensive approach to tackling neurodegenerative diseases. As the biotech landscape evolves, IGC Pharma’s focus on AI integration and innovative therapies positions it well within the competitive market for Alzheimer’s treatments.